$1.80
-0.02 (-1.10%)
Open$1.80
Previous Close$1.82
Day High$1.84
Day Low$1.75
52W High$4.34
52W Low$1.41
Volume—
Avg Volume422.6K
Market Cap77.63M
P/E Ratio—
EPS$-0.65
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,569.4% upside
Current
$1.80
$1.80
Target
$30.05
$30.05
$22.12
$30.05 avg
$38.96
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 11.43M | 10.74M | 10.31M |
| Net Income | -2,402,162 | -1,945,366 | -2,138,218 |
| Profit Margin | -21.0% | -18.1% | -20.7% |
| EBITDA | -3,961,862 | -3,629,854 | -3,514,676 |
| Free Cash Flow | -2,281,552 | -2,429,555 | -1,597,015 |
| Rev Growth | +22.4% | -6.0% | +21.1% |
| Debt/Equity | 1.10 | 1.30 | 1.15 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |